IP Library › Granted Patent US 11,241,490
Granted Patent B2
US 11,241,490 · App. 16/477,258 · Granted Feb 8, 2022

Nucleoside-modified RNA for inducing an immune response against zika virus

Inventors: Drew Weissman (Wynnewood, PA); Norbert Pardi (Philadelphia, PA); Michael Hogan (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania
A61K39/12A61K9/5123A61P31/14A61K2039/53A61K2039/545A61K2039/55A61K2039/55511A61K2039/55555C12N2770/24134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,490
App. No.
16/477,258
Granted
Feb 8, 2022
Kind
B2
Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof.

Claims (16)

1. A composition for inducing an immune response against Zika virus (ZIKV) in a subject, the composition comprising at least one isolated nucleoside-modified RNA molecule encoding at least one ZIKV antigen, wherein the at least one ZIKV antigen comprises the amino acid sequence of SEQ ID NO: 2.

2. The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA molecule comprises at least one modified nucleoside selected from the group consisting of pseudouridine, and 1-methyl-pseudouridine.

3. The composition of claim 1 , wherein the at least one nucleoside-modified RNA comprises the nucleotide sequence of SEQ ID NO: 1.

4. The composition of claim 1 , wherein the composition further comprises an adjuvant.

5. The composition of claim 1 , wherein the at least one nucleoside-modified RNA molecule further encodes at least one adjuvant.

6. The composition of claim 1 , further comprising a lipid nanoparticle (LNP).

7. The composition of claim 6 , wherein the at least one nucleoside-modified RNA is encapsulated within the LNP.

8. The composition of claim 1 , wherein the composition is a vaccine.

9. A method of inducing an adaptive immune response against Zika virus (ZIKV) in a subject comprising administering to the subject an effective amount of the composition of claim 1 .

10. The method of claim 9 , wherein the at least one isolated nucleoside-modified RNA molecule comprises at least one modified nucleoside selected from the group consisting of pseudouridine, and 1-methyl-pseudouridine.

11. The method of claim 9 , wherein the method further comprises administering to the subject an effective amount of an adjuvant.

12. The method of claim 9 , wherein the at least one nucleoside-modified RNA is encapsulated within a LNP.

13. The method of claim 9 , wherein the composition is a vaccine.

14. The method of claim 9 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscualar.

15. The method of claim 9 , wherein the method comprises a single administration of the composition.

16. The method of claim 9 , wherein the method comprises a multiple administrations of the composition.

Continuity (2)
Provisional Application 62444931 · Jan 11, 2017
Related Publication 20190358314A1 · Nov 28, 2019
Cited By (6)
US 12,410,121 US 12,491,261 US 12,583,816 US 12,667,627 US 12,678,515 US 12,714,670